In This Section

2022 Press Program

The AACR Annual Meeting 2022 press program included three in-person press conferences featuring nine newsworthy studies from the Annual Meeting. The AACR also issued news releases on four additional abstracts.

PRESS CONFERENCE: Sunday, April 10, 2022

The AACR hosted the first press conference on Sunday, April 10. AACR Annual Meeting Clinical Trials Committee Co-chair Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, moderated the press conference.

Video of the press conference will be available at a later date.

The following research studies were presented:

Natural Killer Cells Complexed With a Bispecific Antibody May Provide New Treatment Option for Patients With Advanced Lymphoma  

  • Presented by: Yago Nieto, MD, PhD, The University of Texas MD Anderson Cancer Center

KRAS G12C Inhibitor Sotorasib May Offer Long-term Clinical Benefit in Patients with Non-small Cell Lung Cancer

  • Presented by: Grace K. Dy, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York

Recurrent Non-invasive Breast Tumors May Not Always Be Related to the Primary Lesion

  • Presented by: Tanjina Kader, PhD, Peter MacCallum Cancer Centre in Melbourne, Australia

PRESS CONFERENCE: Monday, April 11, 2022

The AACR hosted the second press conference on Monday, April 11. Louis M. Weiner, MD, Georgetown Lombardi Comprehensive Cancer Center, moderated the press conference.

Video of the press conference will be available at a later date.

The following research studies were presented:

Accounting for Genetic Factors that Cause Normal Variations in PSA Levels May Improve the Accuracy of Prostate Cancer Detection

  • Presented by: Linda Kachuri, MPH, PhD, University of California, San Francisco

Pediatric Cancer Patients in Lower- and Middle-Income Countries Faced Significantly Higher Mortality Risk During the COVID-19 Pandemic

  • This study was concurrently published in BMJ Open
  • Presented by: Muhammed Elhadi, MBBCh, University of Tripoli, Libya

RACE Act Increased the Number of Cancer Drugs with Required Studies for Use in Pediatric Patients

  • Presented by: Brittany Avin McKelvey, PhD, Friends of Cancer Research

PRESS CONFERENCE: Tuesday, April 12, 2022

The AACR hosted the third and final press conference on Tuesday, April 12. Ana María López, MD, MPH, MACP, FRCP, Sidney Kimmel Cancer Center, Thomas Jefferson University, moderated the press conference.

Video of the press conference will be available at a later date.

The following research studies were presented:

Novel COVID-19 Vaccine May Provide Protection for Cancer Patients With B-cell Deficiencies

  • Presented by: Claudia Tandler, MSc, University of Tübingen, Germany

Leukemia Patients With Certain Gene Regulation Patterns May Be Less Likely to Respond to CAR T Therapy

  • Presented by: Katherine Masih, National Cancer Institute

Some Latino Children Diagnosed with Acute Lymphoblastic Leukemia Face Higher Risk of Relapse Compared to non-Latino White Children

  • Presented by: Philip Lupo, PhD, Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center at Baylor, and Texas Children’s Cancer and Hematology Center

ADDITIONAL NEWS RELEASES

An AI Model May Predict Elevated Pancreatic Cancer Risk Using Electronic Health Records

  • Presented by: Bo Yuan, PhD candidate, Harvard University

New CAR T-cell Therapy for Solid Tumors Was Safe and Showed Early Efficacy

  • Presented by: John Haanen, MD, PhD, Netherlands Cancer Institute (NKI)

Lung Cancer Patients With a Genetic Variant Linked to Autoimmune Disease May Respond Better to Immunotherapy

  • Presented by: India Allen, BSc, Garvan Institute of Medical Research, St Vincent’s Medical School, Australia

An AI Model Can Help Predict Adverse Events From New Drug Combinations

  • Presented by: Bart Westerman, PhD, Cancer Center Amsterdam